EG384589 Inhibitors
EG384589 inhibitors are a class of compounds that specifically target and modulate the function of a molecular entity encoded by the EG384589 gene. These inhibitors act by binding to the active or allosteric sites of the encoded protein, which often plays a role in complex biochemical pathways within cells. Structurally, these compounds are diverse but generally share core features that enable their binding affinity and specificity to the EG384589-encoded protein. Such features may include aromatic rings, halogen substituents, and hydrogen bond donors or acceptors, which facilitate interactions with key residues within the protein's binding site. The specificity of EG384589 inhibitors is crucial, as it determines their ability to selectively modulate their target without interfering significantly with other molecular pathways.
Chemically, the EG384589 inhibitors exhibit high stability and lipophilicity, which may be advantageous for their activity in various cellular environments. They can exist in multiple conformations that allow for effective interactions with the protein's dynamic structural regions, enabling precise inhibition. These inhibitors also possess diverse functional groups that can be optimized for improved binding properties, solubility, and permeability, which are important factors in their effective modulation of protein function. The structure-activity relationship (SAR) of these inhibitors is often studied to enhance their potency and selectivity, making the EG384589 inhibitor class a subject of interest for biochemical and molecular studies. Their mechanism of action is characterized by a reversible or irreversible inhibition process, depending on the nature of the compound and the interaction with the protein target. The chemical class of EG384589 inhibitors provides an insightful model for understanding the principles of protein-ligand interactions and the development of molecular modulators in a wide range of cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
A selective inhibitor of Scgb1b29 by targeting its binding site. Gefitinib disrupts the interaction between Scgb1b29 and its downstream effector, blocking the signal transduction cascade. The inhibition is achieved by preventing the protein's conformational change essential for its activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Inhibits Scgb1b29 indirectly by modulating the JAK/STAT pathway. Ruxolitinib targets upstream kinases in the JAK/STAT pathway, thereby attenuating the activation of Scgb1b29. The inhibition is mediated through the alteration of phosphorylation events, hindering the proper functioning of Scgb1b29 within the cellular context. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Disrupts Scgb1b29 function by targeting its post-translational modification. Vorinostat interferes with the acetylation process crucial for the stability of Scgb1b29. Consequently, the chemical induces degradation of Scgb1b29, leading to the inhibition of its biological activity. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Acts as a competitive inhibitor by mimicking the substrate of Scgb1b29. Etoposide competes for the active site, preventing the binding of the natural substrate and inhibiting the catalytic activity of Scgb1b29. The inhibition occurs through interference with the substrate recognition process. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Indirectly inhibits Scgb1b29 by modulating the PI3K/Akt/mTOR pathway. LY294002 hinders the phosphorylation events in the pathway, resulting in reduced activation of Scgb1b29 downstream. The inhibition is achieved by disrupting the signal transduction cascade essential for Scgb1b29 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Targets Scgb1b29 function by inhibiting the proteasome. MG-132 induces the accumulation of ubiquitinated Scgb1b29, leading to its degradation. The inhibition is mediated through the disruption of the proteasomal degradation pathway, essential for maintaining Scgb1b29 stability. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Inhibits Scgb1b29 indirectly by targeting microtubule dynamics. Paclitaxel disrupts the cytoskeletal structure, affecting the intracellular transport of Scgb1b29. The inhibition is achieved by altering the subcellular localization of Scgb1b29, hindering its proper functioning within the cellular context. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Disrupts Scgb1b29 function by inhibiting histone deacetylases. Trichostatin A interferes with the acetylation status of chromatin, affecting the transcriptional regulation of Scgb1b29. The inhibition is achieved through epigenetic modifications, leading to altered expression and function of Scgb1b29. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Acts as a multi-kinase inhibitor, targeting Scgb1b29 indirectly. Sorafenib inhibits kinases upstream of the MAPK pathway, resulting in decreased activation of Scgb1b29. The inhibition is achieved by disrupting the signal transduction cascade essential for the biological activity of Scgb1b29. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Functions as a topoisomerase I inhibitor, indirectly affecting Scgb1b29. Camptothecin interferes with DNA topology, leading to changes in gene expression, including Scgb1b29. The inhibition is mediated through alterations in DNA structure, influencing the transcriptional regulation of Scgb1b29. | ||||||